The historical rank and industry rank for Hisamitsu Pharmaceutical Co's EV-to-FCF or its related term are showing as below:
TSE:4530'
s EV-to-FCF Range Over the Past 10 Years
Min: 30.76 Med: 35.33 Max: 40.8
Current: 32.29
During the past 13 years, the highest EV-to-FCF of Hisamitsu Pharmaceutical Co was 40.80. The lowest was 30.76. And the median was 35.33.
TSE:4530's EV-to-FCF is ranked worse than 59.3% of 511
companies
in the Drug Manufacturers industry
Industry Median: 23.55
vs TSE:4530: 32.29
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Hisamitsu Pharmaceutical Co's EV-to-FCF
For the Drug Manufacturers - Specialty & Generic subindustry, Hisamitsu Pharmaceutical Co's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Hisamitsu Pharmaceutical Co's EV-to-FCF Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Hisamitsu Pharmaceutical Co's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Hisamitsu Pharmaceutical Co's EV-to-FCF falls into.
Hisamitsu Pharmaceutical Co's current Enterprise Value is 円166,345 Mil.
Hisamitsu Pharmaceutical Co's Free Cash Flow for the trailing twelve months (TTM) ended in Nov. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was 円0 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Hisamitsu Pharmaceutical Co (TSE:4530) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Hisamitsu Pharmaceutical Co's PE Ratio for today is calculated as:
Hisamitsu Pharmaceutical Co's share price for today is 円3823.00.
Hisamitsu Pharmaceutical Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Nov. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was 円181.024.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Hisamitsu Pharmaceutical Co EV-to-FCF Related Terms
Thank you for viewing the detailed overview of Hisamitsu Pharmaceutical Co's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.
Hisamitsu Pharmaceutical Co (TSE:4530) Business Description
Hisamitsu Pharmaceutical Co Inc is a major pharmaceutical products manufacturer in Japan. The company collaborates with its subsidiaries and associates in operating its business across two segments, The Medical and Related Product segment and the Others segment. The Medical segment represents the company's foremost revenue generating operations. It markets drugs under the Salanpas, Salonsip, Lifecella, Mohrus and Keplat brands, which mainly serve topical medication needs with pain relief creams, gels, sprays, lotions and ointments. The Others segment refers to its miscellaneous businesses such as cable television broadcasting, internet connection, packing materials and insurance. Apart from its primary market in Japan, Hisamitsu has a reach across other regions like North America.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
TSE:4530 has been successfully added to your 